 Andrey Soares
Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Information Interoperability | 1 | 2024 | 3 | 0.870 |
Why?
| | Carcinoma, Renal Cell | 4 | 2026 | 225 | 0.780 |
Why?
| | Computer Systems | 1 | 2022 | 53 | 0.740 |
Why?
| | Kidney Neoplasms | 4 | 2026 | 407 | 0.690 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 724 | 0.640 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2026 | 194 | 0.600 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 270 | 0.520 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2026 | 927 | 0.460 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2026 | 72 | 0.460 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2026 | 261 | 0.380 |
Why?
| | Electronic Health Records | 4 | 2025 | 1163 | 0.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2026 | 1827 | 0.370 |
Why?
| | Urologic Neoplasms | 1 | 2026 | 31 | 0.240 |
Why?
| | Heterocyclic Compounds, 1-Ring | 1 | 2025 | 6 | 0.240 |
Why?
| | Lutetium | 1 | 2025 | 6 | 0.240 |
Why?
| | Radioisotopes | 1 | 2025 | 33 | 0.240 |
Why?
| | Dipeptides | 1 | 2025 | 56 | 0.230 |
Why?
| | Taxoids | 1 | 2025 | 107 | 0.230 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2025 | 53 | 0.220 |
Why?
| | Radiopharmaceuticals | 1 | 2025 | 191 | 0.220 |
Why?
| | Health Level Seven | 1 | 2024 | 2 | 0.220 |
Why?
| | Biological Products | 2 | 2024 | 246 | 0.210 |
Why?
| | Platelet Transfusion | 1 | 2024 | 79 | 0.210 |
Why?
| | Needs Assessment | 1 | 2025 | 392 | 0.190 |
Why?
| | Developing Countries | 1 | 2024 | 308 | 0.190 |
Why?
| | Computers | 1 | 2022 | 68 | 0.180 |
Why?
| | Erythrocyte Transfusion | 1 | 2024 | 211 | 0.180 |
Why?
| | Tobacco Use | 1 | 2022 | 65 | 0.180 |
Why?
| | Computer Communication Networks | 1 | 2021 | 32 | 0.170 |
Why?
| | Programming Languages | 1 | 2021 | 25 | 0.170 |
Why?
| | Decision Support Techniques | 1 | 2025 | 438 | 0.170 |
Why?
| | Tobacco Products | 1 | 2022 | 91 | 0.170 |
Why?
| | Confidentiality | 1 | 2021 | 74 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2026 | 647 | 0.170 |
Why?
| | Immunotherapy | 1 | 2025 | 659 | 0.160 |
Why?
| | Information Storage and Retrieval | 1 | 2021 | 120 | 0.160 |
Why?
| | Natural Language Processing | 1 | 2021 | 103 | 0.160 |
Why?
| | Bias | 1 | 2021 | 208 | 0.160 |
Why?
| | Transgender Persons | 1 | 2023 | 205 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2026 | 758 | 0.150 |
Why?
| | Aged, 80 and over | 6 | 2026 | 8072 | 0.150 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 241 | 0.150 |
Why?
| | Antibodies, Monoclonal | 1 | 2026 | 1474 | 0.140 |
Why?
| | Aged | 10 | 2026 | 25322 | 0.140 |
Why?
| | Language | 1 | 2021 | 323 | 0.140 |
Why?
| | Humans | 18 | 2026 | 143560 | 0.130 |
Why?
| | Prostatic Neoplasms | 1 | 2024 | 1058 | 0.130 |
Why?
| | Artificial Intelligence | 1 | 2021 | 365 | 0.130 |
Why?
| | Treatment Outcome | 6 | 2026 | 11365 | 0.120 |
Why?
| | Pilot Projects | 1 | 2022 | 1838 | 0.120 |
Why?
| | Middle Aged | 10 | 2026 | 35343 | 0.120 |
Why?
| | Retrospective Studies | 7 | 2026 | 16740 | 0.120 |
Why?
| | Male | 13 | 2026 | 71501 | 0.110 |
Why?
| | Algorithms | 1 | 2021 | 1813 | 0.100 |
Why?
| | Female | 12 | 2026 | 77252 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2113 | 0.090 |
Why?
| | Adult | 8 | 2026 | 40012 | 0.090 |
Why?
| | Research | 1 | 2023 | 438 | 0.080 |
Why?
| | Prognosis | 2 | 2026 | 4152 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2025 | 166 | 0.050 |
Why?
| | Orchiectomy | 1 | 2024 | 76 | 0.050 |
Why?
| | Brazil | 1 | 2024 | 177 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2025 | 388 | 0.050 |
Why?
| | Blood Banks | 1 | 2024 | 47 | 0.050 |
Why?
| | Androgen Antagonists | 1 | 2024 | 92 | 0.050 |
Why?
| | Gender Identity | 1 | 2023 | 133 | 0.050 |
Why?
| | Common Data Elements | 1 | 2021 | 14 | 0.040 |
Why?
| | Life Style | 1 | 2024 | 483 | 0.040 |
Why?
| | Survival Rate | 1 | 2026 | 2003 | 0.040 |
Why?
| | Blood Platelets | 1 | 2024 | 390 | 0.040 |
Why?
| | Patient Participation | 1 | 2023 | 434 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2025 | 1095 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 963 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2023 | 498 | 0.040 |
Why?
| | Erythrocytes | 1 | 2024 | 708 | 0.040 |
Why?
| | Age Factors | 1 | 2026 | 3328 | 0.040 |
Why?
| | Weight Loss | 1 | 2024 | 812 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1563 | 0.030 |
Why?
| | United States | 2 | 2024 | 15554 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5308 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2107 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1668 | 0.030 |
Why?
| | Communication | 1 | 2021 | 953 | 0.030 |
Why?
| | Adolescent | 2 | 2024 | 22482 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3380 | 0.020 |
Why?
| | Registries | 1 | 2021 | 2238 | 0.020 |
Why?
| | Pregnancy | 1 | 2024 | 7153 | 0.020 |
Why?
| | Infant | 1 | 2024 | 9981 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 13972 | 0.010 |
Why?
|
|
Soares's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|